NEWS & RESEARCH

Research Papers

Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations

30 August 2022

Research Papers

Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS

5 July 2022

Research Papers

IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies

1 January 2022

Presentations

Kurome CEO, Jan Rosenbaum, to Be a Featured Speaker at the Next Generation Kinase Inhibitors Summit

24 February 2022

Presentations

CCHMC Grand Rounds Presented by Jan Rosenbaum and Dan Starczynowski

15 February 2022

Press Releases

Kurome Therapeutics: Rosenbaum’s Leadership Journey To Potentially Deliver Life-Saving Cancer Treatment

1 October 2021

Press Releases

Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers

10 June 2021

Research Papers

Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets

10 February 2021

News Articles

TechOhio: This Cincinnati Startup is Innovating Targeted Cancer Treatments

26 January 2021

Press Releases

Kurome Therapeutics launched to develop therapies targeting cancer's ability to evade treatment

29 April 2020

News Articles

P&G alum tapped as CEO of Cincinnati Children’s spin-out company

29 April 2020

Cincinnati Business Courier

Research Papers

Targeting AML-associated FLT3 mutations with a type I kinase inhibitor

Jones LM et al - 2020

Journal of Clinical Investigation

Research Papers

Overcoming adaptive therapy resistance in AML by targeting immune response pathways

Melgar K et al – 2019

Science Translational Medicine

Research Papers

U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.

Smith MA et al – 2019

Nature Cell Biology

Research Papers

Chronic immune response dysregulation in MDS pathogenesis.

Barreyro L et al – 2018

Blood

Research Papers

IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.

Adams AK et al - 2015

Oncotarget

Research Papers

IRAK signalling in cancer

Rhyasen GW and Starczynowski DT – 2015

British Journal of Cancer

Research Papers

IRAK1: Oncotarget in MDS and AML

Beverly LJ and Starczynowski DT - 2014

Oncotarget

Research Papers

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome

Rhyasen GW et al – 2013

Cancer Cell

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.